
What smart money is saying about ADMA Biologics
1 fund in our archive has pitched ADMA Biologics — most recently Renaissance IM Small Cap Growth in June 2025.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Renaissance IM Small Cap GrowthJune 2025
ADMA Biologics is a commercial-stage biopharma company focused on plasma-based biologics for immune deficiencies and infectious disease prevention, with strong growth prospects and a target of $1 billion in revenue by 2030.
Read the full thesis
Read every full thesis on ADMA Biologics
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→